GABA活性神经元功能障碍是脊髓小脑动3中的基础
Animesh Banerjee1, Moumita Chatterjee1, Kah Junn Tan1
1Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR), 61 Biopolis Drive, Singapore138673.
Disease models & mechanisms
|September 18, 2025
概括
研究人员在腹部神经 (VNC) 中确定了特定的神经元,当功能失调时会引起震. 这项研究强调GABAergic神经元功能障碍是脊髓小脑动3 (SCA3) 震的关键因素.
科学领域:
- 神经科学是一个神经科学.
- 遗传学 是一个遗传学.
- 运动障碍 运动障碍
背景情况:
- 震是神经退行性疾病的常见症状,如脊髓小脑动3 (SCA3).
- 震背后的精确神经机制仍然不太清楚.
- 之前的工作为SCA3建立了一个Drosophila模型,具有类似的步态和震特征.
研究的目的:
- 在SCA3.3的Drosophila模型中确定负责震的特定神经元群体.
- 为了研究GABAergic神经元在运动控制和震中的作用.
- 为了验证基于特征学习的腿部细分和跟踪 (FLLIT) 方法的实用性.
主要方法:
- 在Drosophila中进行功能性遗传查.
- 成人开始的基因表达和神经元活动的操纵.
- RNA测序和随后的功能验证.
- 使用基于特征学习的腿部细分和跟踪 (FLLIT) 进行步态分析.
主要成果:
- 发现特定腹腔神经 (VNC) 神经元群体的功能障碍是震的必要和充分原因.
- 成人开始突变ATXN3的表达或这些VNC神经元的低激活引起震.
- RNA测序和功能实验涉及GABAergic神经元,而不是其他神经递质类型,在震.
- 在VNC中,大约30个GABAergic神经元的子集被确定为顺运动的必要部分.
结论:
- 在SCA3 Drosophila模型中的震起源于VNC中的特定GABAergic神经元的功能障碍.
- 这些发现确定了GABAergic VNC神经元在保持平稳行走方面发挥的关键作用.
- FLLIT方法是解剖复杂的运动控制机制的一个有价值的工具.
相关概念视频
01:18Antiepileptic Drugs: GABAergic Pathway Potentiators
1.2K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.2K
01:20Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
831
Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
831
01:26Chemical Synapses
11.3K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
11.3K
01:26Chemical Synapses
4.3K
Chemical synapses are specialized sites between two neurons or between a neuron and a non-neuronal cell like a muscle, glandular or sensory cell.
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
Because chemical synapses depend on the release of neurotransmitter molecules from synaptic vesicles to pass on their signal, there is an approximately one millisecond delay between when the axon potential reaches the presynaptic terminal and when the neurotransmitter leads to opening of postsynaptic ion channels. Additionally, this signaling is...
4.3K
01:15Parkinson's Disease: Overview
1.8K
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
1.8K
01:24Parkinson's Disease: Treatment
987
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
987